Demo
ABCL Nasdaq· AbCellera Biologics Inc.
FundamentalsNews digest Peer analysis
Login
ABCL Nasdaq· AbCellera Biologics Inc.
Earnings report Q4 2023

ABCL Reports Strong Revenue Growth in Latest Quarter

Segments of Revenue

ABCL reported total revenue of $38.03 million in the latest quarter. The revenue was generated from the following segments:

  • Research fees: $35.56 million
  • Licensing revenue: $0.97 million
  • Milestone payments: $1.50 million
  • Royalty revenue: Not reported

Strengths

ABCL demonstrated strong revenue growth in the latest quarter, with a significant increase compared to the previous year. The company's research fees revenue increased from $19.08 million in the previous year to $35.56 million, indicating a robust demand for its research services. This growth can be attributed to ABCL's strong reputation in the biologics industry and its ability to attract clients for research collaborations.

Challenges

ABCL did not report the revenue from its royalty segment in the latest quarter, making it difficult to assess the overall performance of this revenue stream. The company's operating expenses also increased over the years, which may impact its profitability in the long run. ABCL should closely monitor its expenses to ensure sustainable growth.

Noteworthy

ABCL's revenue from licensing and milestone payments showed a decline compared to the previous year. Licensing revenue decreased from $20.78 million to $0.97 million, while milestone payments decreased from $8 million to $1.50 million. This decline could be attributed to the timing of licensing agreements and milestone achievements during the quarter.

Summary

ABCL reported strong revenue growth in the latest quarter, primarily driven by an increase in research fees. The company's reputation in the biologics industry and its ability to attract research collaborations contributed to this growth. However, ABCL should closely monitor its operating expenses and address the decline in licensing and milestone payments to ensure sustained profitability. Overall, ABCL's performance in the latest quarter reflects its position as a key player in the biologics research industry.

Source documents

Form 10-K  filed on Feb 20, 2024
36 pages scanned

Reference data

Company financials Q4 revenue 9.2M
Analyst estimates Q4 EPS beat by 24.45%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.